B+
Bull case
20%
Probability
Target price
$126.00
+25.5% vs current
RVTY
RevvityANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$111.00
+10.6% vs current
B-
Bear case
30%
Probability
Target price
$86.00
-14.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-28
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+55.0
Score
AI commentary
The immediate reaction was mildly positive in the available news context, but the tone stays mixed because investors also had to digest the lower FY26 pro forma EPS guide and margin compression. Analyst-revision evidence is limited rather than decisively bullish, so this remains a cautious monitoring setup around the Q2 2026 divestiture agreement checkpoint and subsequent 2027 regulatory close path.
RankAlpha Sentiment Codex - 2026-05-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-05eventQ1 beat and FY26 outlook updateMedium impact
Revvity reported Q1 revenue of $711 million and adjusted EPS of $1.06, with pro forma revenue of $687 million and pro forma adjusted EPS of $1.04; management also guided FY26 pro forma revenue to $2.81-$2.84 billion and pro forma adjusted EPS to $5.20-$5.30 [#8-K-2026-05-05].
2026-06-30eventQ2 2026 China Immunodiagnostics definitive-agreement checkpointMedium impact
Revvity said it entered a letter of intent to divest its China Immunodiagnostics business, which represented about 6% of FY2025 revenue, and expects a definitive agreement to be signed in the second quarter of 2026; closing is expected in 2027 after required regulatory approvals [#8-K-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-28 • Updated nightlySource: Internal modelMethodology